Flow Cytometry Stem Cell Enumeration Kit Designed to Ease Stem Cell Transplantation
|
By LabMedica International staff writers Posted on 07 Mar 2012 |
|
Image: The BD Stem Cell Enumeration (SCE) Kit (Photo courtesy of BD Biosciences).
A dedicated flow cytometry stem cell enumeration kit is aimed at the rapidly growing stem cell transplantation market.
High-dose chemotherapy (HDC) with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkin's lymphoma. Stem cell transplantation with cell selection is performed after HDC in an effort to restore a cancer patient’s blood and immune cell production capacity, which is destroyed in this aggressive form of cancer treatment. Improvements in transplantation techniques, including the wider use of cell selection, have also contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. As a result, HDC with transplantation has grown at an average annual rate of 21% over the past 10 years.
To aid clinicians and researchers working in the stem cell transplantation field BD Biosciences (Franklin Lakes, NJ, USA) has introduced their BD Stem Cell Enumeration (SCE) Kit for use on the BD FACSCanto II and BD FACSCalibur flow cytometers.
The SCE Kit is for in vitro diagnostic use and provides a single-tube, single-platform assay for accurate, reproducible, and rapid enumeration of CD34+ hematopoietic and progenitor cells in a wide range of stem cell sources. Sample types that may be analyzed with the SCE Kit include normal and mobilized peripheral blood, material from fresh or frozen leukophoresis, bone marrow, and cord blood.
The BD SCE assay allows simultaneous enumeration of total viable dual-positive CD45+/CD34+ hematopoietic stem cells in absolute counts of CD34+ cells/microliter and the percentage of viable leucocytes (CD45+) that are CD34-positive (CD34+). A set of premixed antibodies reduces reagent preparation time to meet productivity demands of clinical labs. In addition, the SCE assay incorporates BD’s proprietary Trucount tubes, which allow determination of absolute cell count, thereby eliminating variability associated with hematology-derived absolute counts.
Related Links:
BD Biosciences
 assay.jpg)
High-dose chemotherapy (HDC) with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkin's lymphoma. Stem cell transplantation with cell selection is performed after HDC in an effort to restore a cancer patient’s blood and immune cell production capacity, which is destroyed in this aggressive form of cancer treatment. Improvements in transplantation techniques, including the wider use of cell selection, have also contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. As a result, HDC with transplantation has grown at an average annual rate of 21% over the past 10 years.
To aid clinicians and researchers working in the stem cell transplantation field BD Biosciences (Franklin Lakes, NJ, USA) has introduced their BD Stem Cell Enumeration (SCE) Kit for use on the BD FACSCanto II and BD FACSCalibur flow cytometers.
The SCE Kit is for in vitro diagnostic use and provides a single-tube, single-platform assay for accurate, reproducible, and rapid enumeration of CD34+ hematopoietic and progenitor cells in a wide range of stem cell sources. Sample types that may be analyzed with the SCE Kit include normal and mobilized peripheral blood, material from fresh or frozen leukophoresis, bone marrow, and cord blood.
The BD SCE assay allows simultaneous enumeration of total viable dual-positive CD45+/CD34+ hematopoietic stem cells in absolute counts of CD34+ cells/microliter and the percentage of viable leucocytes (CD45+) that are CD34-positive (CD34+). A set of premixed antibodies reduces reagent preparation time to meet productivity demands of clinical labs. In addition, the SCE assay incorporates BD’s proprietary Trucount tubes, which allow determination of absolute cell count, thereby eliminating variability associated with hematology-derived absolute counts.
Related Links:
BD Biosciences
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Silver Member
PCR Plates
Diamond Shell PCR Plates
Gold Member
Hybrid Pipette
SWITCH
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read more
Molecular Diagnostics
view channel
Microfluidic Device Predicts Pancreatic Cancer Recurrence After Surgery
Pancreatic ductal adenocarcinoma is one of the deadliest cancers, difficult to detect early, and prone to recurring in nearly 70% of patients after treatment. Its location deep in the abdomen and its aggressive... Read more
New Molecular Test Simultaneously Detects Three Major Fungal Infections
Serious fungal infections associated with soil exposure remain difficult to diagnose promptly, especially in regions where Histoplasma, Blastomyces, and Coccidioides are endemic. Many patients present... Read more
Hematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Immunology
view channel
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Microbiology
view channel
Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. Despite TB infecting 10 million people yearly, the... Read more
15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
Distinguishing minor childhood illnesses from potentially life-threatening infections such as sepsis or meningitis remains a major challenge in emergency care. Traditional tests can take hours, leaving... Read more
High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Pathology
view channel
AI Tool to Transform Skin Cancer Detection with Near-Perfect Accuracy
Melanoma continues to be one of the most difficult skin cancers to diagnose because it often resembles harmless moles or benign lesions. Traditional AI tools depend heavily on dermoscopic images alone,... Read more
Unique Immune Signatures Distinguish Rare Autoimmune Condition from Multiple Sclerosis
Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) is a rare autoimmune disorder in which the immune system attacks the myelin sheath in the central nervous system. Although symptoms... Read more
Technology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read more
Industry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more
